Biomarker Dilemma Persists With Immunotherapy in Bladder Cancer – OncLive
OncLive |
Biomarker Dilemma Persists With Immunotherapy in Bladder Cancer
OncLive In metastatic bladder cancer, cytotoxic chemotherapy using a cisplatin backbone has long been the standard of care. First-line therapy using a dose-dense chemotherapy combination of methotrexate, vinblastine, doxorubicin, and cisplatin, along with … |
